Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study

Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder

“…Older age at onset was reported as a risk predictor of visual and motor disability in NMOSD (27). The late-onset course was associated with rapid disease progression and long-term disability (28)(29)(30), which might be explained by malfunctions in self-repair and blunted long-lived memory responses in aging individuals (31).…”

Neuromyelitis optica spectrum disorder: epidemiology, pathogenesis, diagnosis, treatment, and prognosis

“…Ûmaus li gos pa si reið ki mo ar pa si kar to ji mo gy dy mas yra la bai svar bus, nes ûmiø ata kø me tu ga li bû ti stip riai su trikdy tos neu ro lo gi nës funk ci jos ar net ið tik ti mir tis, o jø kar toji ma sis le mia sun kià ne ga lià. Pa vyz dþiui, ty ri me, ku ria me ver tin tas imu no sup re si niø vais tø, ski ria mø pa lai ko ma jam NMOSD gy dy mui, efek ty vu mas, pa ste bë ta, kad ti ria mø jø, ser gan èiø NMOSD, re gë ji mo su tri ki mo sun ku mas sie jamas su anks ty vo ûmiø ata kø gy dy mo veiks min gu mu, o palai ko ma sis imu no sup re si nis gy dy mas jam áta kos ne tu rë jo [20]. Pra di nis NMOSD gy dy mas yra di de lës me til pred nizo lo no do zës, t. y.…”

“…Re mian tis sis te mi nës ap þval gos ir meta a na li zës, ku rio je pa ly gin tas gy dy mo vi sais 3 vais tais veiks min gu mas, duo me ni mis, ri tuk si ma bas la biau siai suma þi no me ti ná re ci dy vø skai èiø, o var to jant mi ko fe no la to mo fe ti lá pa ste bë ta ma þiau siai ne pa gei dau ja mø reið ki niø [27]. Shi su ben dra au to riais at lik ta me pros pektyviniame ko hor ti nia me ty ri me pa ste bë ta, kad, var to jant tiek azatiop ri nà, tiek mi ko fe no la to mo fe ti lá, reikð min gai su ma þëja re ci dy vø skai èius ir nu sta to mos ma þes nës EDSS ba lø ver tës, ly gi nant su ti ria mai siais, ku riems bu vo skir ti tik gliu ko kor ti koi dai ar vi sai ne skir tas gy dy mas imu no supre san tais [20]. Ta èiau, nors skir tu mas tarp ðiø vais tø veiks min gu mo ne bu vo pa ste bë tas, di dþio ji da lis pa cien tø ge riau to le ra vo gy dy mà mi ko fe no la to mo fe ti liu ga li mai dël to, kad gy do miems aza tiop ri nu pa si reið kë dau giau nepa gei dau ja mø reið ki niø, to kiø kaip leu ko pe ni ja, trom boci to pe ni ja, he pa to tok sið ku mas, plau kø slin ki mas ir kt.…”

Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis

“…In our study, the database we searched includes not only the English database but also the Chinese database. The retrieval time is limited to June 2020, and we will add three retrospective studies involving 471 patients with NMOSD, [29][30][31] which makes the retrieval literature more comprehensive. At the same time, the conclusions of the previously published literature about the clinical effect of MMF were inconsistent.…”